Back

Merck & Company Inc

Ticker: MRK ISIN: US58933Y1055
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Market cap
$210.34B
P/E
12.98
Forward P/E
9.43
Profit margin
25.79%
Revenue growth QoQ
-1.90%
Div. yield
3.82%
Beta
0.39
$150.66 -1.24%
Price as of 2026-08-24 · NYSE

Performance by timeframe

Rolling returns
1 Month +15.22%
6 Months +23.35%
1 Year +82.51%
5 Years +18.14% p.a.+129.97%
10 Years +13.05% p.a.+240.54%
Since inception +7.51% p.a.+510.35%
Calendar year returns
YTD +45.23%
2025 +9.79%
2024 -6.26%
2023 +1.01%
2022 +49.42%
2021 +1.75%

Key stats

Market cap
210.34B
P/E
12.98
Dividend yield
3.82%
Beta
0.39
52-week range
72.58 - 116.37
50-day MA
81.09
200-day MA
88.77
Section 1

Business overview

Company profile data from fundamentals.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and ant

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 35.42%
ROA 13.01%
Profit margin 25.79%
Operating margin 37.47%
PEG ratio 0.83
Revenue/share TTM 25.21
Revenue TTM 63.62B
EBITDA 28.33B
Gross profit TTM 49.25B
Beta 0.39

Valuation

Trailing P/E 12.98
Forward P/E 9.43
P/B 4.29
P/S 3.31
EV/EBITDA 9.47
EV/Revenue 3.73

ESG Scores

Total ESG 28.4
Environment 3.1
Social 15.6
Governance 12.7
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 8.93
Quarterly earnings growth -17.80%
Revenue TTM 63.62B
Reported quarters 124
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 3.82%
Forward annual div. yield 3.85%
Dividend per share 3.1600
Payout ratio 42.41%
Ex-dividend date 2025-09-15
Next dividend date 2025-10-07
Split factor 1048:1000
Last split date 2021-06-03
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $101.79
Analyst rating 4.0385

Ownership & short interest

Shares outstanding 2.50B
Shares float 2.49B
Institutional ownership 80.43%
Insider ownership 6.70%
Short ratio 1.92
Short % of float 1.15%

Details

Instrument metadata and source update timestamps.

Symbol MRK
Name Merck & Company Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US58933Y1055
Country USA
Code + exchange MRK.NYSE
Last price date 2025-08-15
Fundamentals updated 2025-08-16

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.